Rootloc Enters US Market with Artificial Knee Joint

Rootloc has announced its entry into the US market with its artificial knee joint, CentLoc. This marks a significant milestone for the company, opening up new opportunities in the world’s largest market for orthopedic devices.

Rootloc’s Strategic Move

Rootloc’s move into the US was strategic. They partnered with Aegis Spine, a subsidiary of L&K Biomed, which has an established network of hospitals in the US.

• Rootloc shipped products worth $220,000 (about 3.2 billion won).
• The demand for Korean-made artificial knee joints is high in US hospitals.
• The US market represents over 50% of the global artificial joint market.

Benefits and Challenges

The US market provides high profitability due to higher medical insurance reimbursement rates compared to the domestic market. However, entering this market means addressing several challenges:

• Obtaining US FDA approval, which Rootloc successfully achieved.
• Competing with well-established foreign brands.

Rootloc’s Background and Achievements

Rootloc, founded in 2014, has already marked several achievements:

• Developed CentLoc tailored to Korean body types.
• Established local production facilities in Cheonan, Korea.
• Listed on the KOSDAQ stock exchange, planning for further growth.

Key Milestones for Rootloc:

1. Local Production: Rootloc’s production facility in Cheonan helps meet the growing demand both domestically and internationally.

2. FDA Approval: Achieving FDA approval is critical for ensuring product quality and safety in the US market.

3. Listing and Expansion: Rootloc went public in December 2020 and aims to leverage the KOSDAQ Fast Track system for further expansion.

Future Prospects

Rootloc’s entry into the US market is expected to significantly boost its revenue and growth prospects. Here’s what this means for you as an industry observer:

• Watch for potential impacts on both the domestic and international orthopedic markets.
• Keep an eye on Rootloc’s competitors and how they respond to this new entrant.
• Consider the implications of Rootloc’s success on innovation and product development in Korea.

Rootloc’s strategic entry into the US market with CentLoc represents a major step in their international expansion. This move highlights both the potential and challenges faced by companies looking to enter the competitive US medical device market.

Table of Contents:

1. Introduction
   • Overview of Rootloc’s entry into the US market with CentLoc
   • Significance of this milestone for Rootloc and the orthopedic industry
2. Rootloc’s Strategic Move
   • Discussion of Rootloc’s partnership with Aegis Spine
   • Overview of initial product shipments and market demand for Korean-made knee joints
   • Insights on the US market’s share of the global artificial joint market
3. Benefits and Challenges
   • Profitability potential in the US due to higher reimbursement rates
   • Challenges faced by Rootloc, including FDA approval and competition
4. Rootloc’s Background and Achievements
   • Company history and founding in 2014
   • Development of CentLoc tailored to specific anatomical needs
   • Establishment of local production facilities in Cheonan
5. Key Milestones for Rootloc
   • Importance of local production in addressing demand
   • Achieving FDA approval for product safety and quality assurance
   • Listing on the KOSDAQ stock exchange and plans for further growth
6. Future Prospects
   • Expected revenue boosts and growth opportunities in the US market
   • Potential impacts on domestic and international orthopedic markets
   • Observations on competitive dynamics post-entry
7. Conclusion
   • Recap of Rootloc’s significant strategic entry into the US market with CentLoc
   • Discussion on the implications for innovation and product development in Korea